Aachen papers per year
Papers 539
-
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +9 more
1citations -
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter2021 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +5 more
1citations -
ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry
Katharina Kohlbrenner, Norbert Galuschek, Alice Charlotte Fabarius, Marcel Reiser, Klaus Fenchel, Eva Eßeling, +23 more
1citations -
Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmaï Hakimi, Barbara Czech, Sam Williamson, +4 more
1citations -
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations
Most active Aachen authors
-
Tim H. Brümmendorf 16,145 citations overall53 papers
-
Steffen Koschmieder 11,677 citations overall46 papers
-
Jens Panse 10,288 citations overall40 papers
-
Joost S.P. Vermaat 3,482 citations overall40 papers
-
Linda Köster 1,844 citations overall39 papers
-
Edgar Jost 3,752 citations overall31 papers
-
Dirk‐Jan Eikema 1,017 citations overall29 papers
-
Hendrik Veelken 10,266 citations overall25 papers
-
Fabian Beier 3,900 citations overall23 papers
-
Martina Margrit Crysandt 2,348 citations overall23 papers
-
Luuk A. Gras 5,079 citations overall22 papers
-
JESSICA T. VERMEULEN 10,466 citations overall20 papers
-
Liesbeth C. de Wreede 4,718 citations overall18 papers
-
Régis Peffault de Latour 20,463 citations overall14 papers
-
Antonio Maria Risitano 16,882 citations overall14 papers